BioMed X

New Research Team for Multispecific Biologics in Collaboration with Daiichi Sankyo Starts at the BioMed X Institute in Heidelberg

The new research team will work on multispecific biologics to target innovative pathways in the tumor microenvironment (TME) 23 October 2025 -- Heidelburg, Germany -- BioMed X, a leading innovation hub for pharma, today announced the start of a new research team at its Heidelberg institute for multispecific biologics in the field of immuno-oncology in collaboration with...

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies 6 February 2025 -- Heidelberg, Germany -- German independent research institute BioMed X announces the successful completion of its oncology research project in...

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy

German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors 14 January 2025 -- Heidelberg, Germany -- BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo...

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

HEIDELBERG, Germany, August 1, 2022 / B3C newswire / -- BioMed X, a German independent research institute, announces the start of its new research project ëExtrachromosomal DNA in Cancerí (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA...
BioMed X GmbH Im Neuenheimer Feld 515 69120 Heidelberg

+49 6221 426 11 0